Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) is set to join the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET. Investors can access the live webcast via Royalty Pharma’s “Events” page, where it will be archived for at least 30 days.

Royalty Pharma, founded in 1996, specializes in acquiring biopharmaceutical royalties. The company collaborates with various innovators across the biopharmaceutical sector and currently holds royalties for over 35 commercial products, enhancing the funding of innovation within the industry.

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5^th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to cofund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 13 development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What is Royalty Pharma's participation in the Evercore ISI HealthCONx Virtual Conference?

Royalty Pharma will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET.

Where can I watch the Royalty Pharma webcast from the HealthCONx Conference?

The webcast can be accessed from Royalty Pharma’s 'Events' page on their website.

How long will the Royalty Pharma HealthCONx Conference webcast be available?

The webcast will be archived for a minimum of thirty days.

What does Royalty Pharma do?

Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation directly and indirectly in the industry.

How many commercial products does Royalty Pharma have royalties on?

Royalty Pharma currently holds royalties on more than 35 commercial products.